(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

http://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

http://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Latest News Releases From The Newsroom

Pfizer's RSV Vaccine Approval, Victoria's Secret Misses Estimates, nCino and PVH Surpass Expectations: Stock Market Recap

June 01st, 2023

Pfizer Inc. (NYSE: PFE), a global pharmaceutical company specializing in vaccines and medicines, announced that its bivalent RSV prefusion F (RSVpreF) vaccine, ABRYSVO, has received approval from the U.S. Food and Drug Administration (FDA).  . Read more

Xylem, Liberty Latin America, Saga Communications, Telefonica Brasil, Terns Pharma, NICE: Analyst Ratings and Price Targets Hint at Potential Upsides

June 01st, 2023

Xylem Inc. (NYSE: XYL) has received an upgrade from Neutral to Outperform by Robert W. Baird, with the price target raised from $122 to $135.  On Wednesday, $XYL closed at $100.20, indicating a potential upside of $34.80 or 34.72% based on th. Read more

Promising Findings from HOOKIPA's HPV16+ Head and Neck Cancer Study; Chewy Beats Estimates, C3.ai Revenue Outlook Disappoints

June 01st, 2023

HOOKIPA Pharma Inc. (Nasdaq: HOOK) has released promising preliminary data from its Phase 2 study of HB-200 in combination with pembrolizumab, offering hope for patients with recurrent/metastatic Human Papillomavirus 16-positive (HPV16+) head and nec. Read more

FTC and DOJ Charge Amazon with Violating Children’s Privacy Law by Keeping Kids’ Alexa Voice Recordings Forever and Undermining Parents’ Deletion Requests

May 31st, 2023

Proposed order to require Amazon to pay $25 million and delete children’s data, geolocation data, and other voice recordings Washington D.C. / CRWE PRESS RELEASE / May 31, 2023  -  The Federal Trade Commission and the Department of. Read more

Chevron, Nevro, America Movil, Hillman Solutions, Grupo Televisa, and ACNB - Assessing Potential Upside and Price Targets

May 31st, 2023

Chevron Corporation (NYSE: CVX), a multinational energy corporation, has been upgraded from Underweight to Neutral by JP Morgan. The price target for $CVX has also been raised from $161 to $170 based on the firm's view.  On Wednesday, $CV. Read more

Akebia Therapeutics, MDxHealth, Avis Budget, argenx, Five9, Inventiva: Analyst Upgrades and Initiations Point to Potential Upsides

May 31st, 2023

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company, received an upgrade from Neutral to Overweight by Piper Sandler, with the price target raised from $2 to $4.  On Wednesday, $AKBA closed at $1.04, indicating a potential u. Read more

Better-Than-Expected Results: Nordstrom and NetApp Thrive, Okta and Salesforce Encounter Market Headwinds

May 31st, 2023

Nordstrom, Inc. (NYSE: JWN), a renowned fashion retailer with a presence in the United States and Canada, reported first quarter 2023 adjusted earnings per share (EPS) of $0.07, surpassing the consensus estimate of a loss of $0.08 per share.  . Read more

FDA Conducts Retailer Inspection Blitz, Cracks Down on Illegal Sales of Popular Disposable E-cigarettes

May 31st, 2023

Washington D.C. / CRWE PRESS RELEASE / May 31, 2023 -  Today, the U.S. Food and Drug Administration issued warning letters to 30 retailers, including one distributor, for illegally selling unauthorized tobacco products. The unauth. Read more

Pre-Market Movers: Marker Therapeutics Surges on MT-601 Potential, Trevena on Milestone Payment

May 31st, 2023

Marker Therapeutics, Inc. (Nasdaq: MRKR) shared positive pre-clinical data regarding their T cell product candidate, MT-601, which targets multiple tumor-associated antigens (multiTAA) in lymphoma cells, including those resistant to CD19 CAR T cell t. Read more

Advance Auto Parts Q1 Results Fall Short of Consensus, Lowers Outlook; iRhythm Technologies Reveals FDA Warning Letter

May 31st, 2023

The first quarter of 2023 proved to be challenging for Advance Auto Parts, Inc. (NYSE: AAP), as the company reported diluted earnings per share (EPS) of $0.72, falling short of the consensus estimate of $2.57.  Tom Greco, the president and ch. Read more